Together, we reach far beyond the skin
A truly global platform dedicated to medical dermatology
Building on a century of experience with breakthrough medicines, the broadest global portfolio in medical dermatology, and a proven innovation model — we are powering progress.
What we do
Shaping the future of what’s next
Get to know our ambition of building strategic partnerships and alliances to make a true difference in the lives of people living with skin diseases.
Innovating to address patient needs
LEO Pharma is developing an even deeper understanding of hard-to-treat skin diseases by forging external partnerships with innovators while we evolve our current offerings.
Improving people’s lives with innovative treatments
We build on deep patient insights in researching and developing new medicines to treat skin diseases.
Featured news
Media
LEO Pharma announces key results of Phase 2 TRAPEDS-1 trial evaluating pharmacokinetics and safety of tralokinumab in children with moderate-to-severe atopic dermatitis
LEO Pharma announces key results of Phase 2 TRAPEDS-1 trial evaluating pharmacokinetics and safety of tralokinumab in children with moderate-to-severe atopic dermatitis TRAPEDS-1 is a Phase 2 trial…
Media
LEO Pharma’s net-zero and emissions reduction targets validated by SBTi
LEO Pharma’s net-zero and emissions reduction targets validated by SBTi LEO Pharma has achieved Science Based Targets initiative (SBTi) validation for its net-zero climate targets, including its ambition…
Media
LEO Pharma delivers 9% revenue growth at CER in Q1 2026 and strengthens innovation pipeline
LEO Pharma delivers 9% revenue growth at CER in Q1 2026 and strengthens innovation pipeline Ballerup, Denmark, 5 May, 2026 – In Q1 2026, LEO Pharma delivered robust revenue…
At a glance
LEO Pharma is a global leader in medical dermatology. We deliver innovative treatments for skin diseases, building on a century of experience with breakthrough medicines in healthcare.
Group revenue growth (CER)
DKK million/% in 2025
10%
Adjusted EBITDA margin
DKK million/% in 2025
16%
Patients served annually
In 2025
+100m